9 completed, 5 terminated, 1 unknown, 1 withdrawn. 16 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 9, Terminated 5, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow Cilengitide: new trials by email Literature Review of Cilengitide trials Research Report on Cilengitide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) Cilengitide, Bevacizumab, Questionnaire - Glioblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-06-01 | 2018-01-19 | |
| Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents Cilengitide, Temozolomide - Gliomas | Phase 2 | Terminated | Martin-Luther-Universität Halle-Wittenberg | 28 | 2012-01-01 | 2015-07-21 |
| Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene Cilengitide - Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 | Phase 2 | Unknown | Northern Sydney and Central Coast Area Health Service | 48 | 2009-11-01 | 2011-07-26 |
| Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma Cetuximab, Cilengitide EMD 121974 - Glioblastoma | Phase 2 | Terminated | Bart Neyns | 12 | 2009-09-01 | 2012-03-22 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide - Glioblastoma | Phase 2 | Completed | EMD Serono | 265 | 2009-03-01 | 2017-01-30 |
| Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) Cilengitide, Cetuximab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 232 | 2009-02-01 | 2017-01-13 |
| Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Cilengitide 2000 mg once weekly, Cilengitide 2000 mg twice weekly, Cetuximab - Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 184 | 2008-10-01 | 2014-04-30 |
| Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy cilengitide, laboratory biomarker analysis, pharmacological study - Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2018-08-01 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme cilengitide, temozolomide, radiation therapy - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 112 | 2005-04-01 | 2016-02-25 |
| Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme cilengitide, therapeutic conventional surgery, pharmacological study - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 30 | 2005-01-01 | 2017-06-14 |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer cilengitide, laboratory biomarker analysis - Recurrent Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 106 | 2005-01-01 | 2013-02-28 |
| Cilengitide in Treating Patients With Prostate Cancer cilengitide - Recurrent Prostate Cancer, Stage I Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2005-01-01 | 2016-04-28 |
| Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Cilengitide 500 mg, Cilengitide 2000 mg - Glioblastoma Multiforme | Phase 2 | Completed | EMD Serono | 81 | 2004-10-13 | 2019-04-16 |
| Cilengitide in Treating Patients With Acute Myeloid Leukemia cilengitide - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 70 | 2004-07-01 | 2013-01-24 |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma cilengitide, pharmacological study, laboratory biomarker analysis - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 56 | 2004-03-01 | 2013-06-05 |
| EMD 121974 in Treating Patients With Progressive or Recurrent Glioma cilengitide - Brain and Central Nervous System Tumors | Phase 1 / Phase 2 | Completed | New Approaches to Brain Tumor Therapy Consortium | 2000-09-01 | 2013-06-24 |
Glioblastoma (9) · Astrocytoma (3) · Brain Neoplasms (3) · Gliosarcoma (3) · Recurrence (3) · Oligodendroglioma (2) · Prostatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Congenital Abnormalities (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Leukemia, Erythroblastic, Acute (1)
National Cancer Institute (NCI) (7) · EMD Serono (2) · Merck KGaA, Darmstadt, Germany (2) · Bart Neyns (1) · M.D. Anderson Cancer Center (1) · Martin-Luther-Universität Halle-Wittenberg (1) · New Approaches to Brain Tumor Therapy Consortium (1) · Northern Sydney and Central Coast Area Health Service (1)
United States (10) · Germany (4) · Belgium (3) · France (2) · Italy (2) · Poland (2) · Spain (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · Hungary (1) · Ireland (1) · Switzerland (1)
Maha Hussain (2) · Andriy Markivskyy, MD (1) · Bart Neyns (1) · Christof M. Kramm, MD (1) · Jan Vermorken, MD, PhD (1) · Kevin Kim (1) · Louis B. Nabors, MD (1) · Louis B. Nabors, Prof. Dr. (1) · Louis Nabors, MD (1) · Mark Gilbert (1) · Mark R. Gilbert, MD,BS (1) · Srdan Verstovsek (1) · Tobey MacDonald (1)
PMID 17470857, PMID 18981465, PMID 21049281, PMID 22517399, PMID 24567516, PMID 25939894, PMID 36346112
2009 (2), N01CM62202 (2), 2008 (1), N01CM62206 (1), U01CA062399 (1), U01CA062475 (1), U10CA098543 (1)